Treatment was well tolerated but activity of single-agent immunotherapy was disappointing with only 4.6% of patients in cohort A responding to therapy; median progression-free survival (PFS) was two months (95% CI 1.9–2.0) and no difference in terms of response rate between patients with PD-L1 positive and PD-L1 negative tumours was observed. The gene discussed is CD274; the disease is neoplasm.